This article is more than 5 years old. Information may no longer be current.

VIDEO: Consistent safety found in long-term extension studies of tofacitinib for rheumatoid arthritis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — At the American College of Rheumatology Annual Meeting, Janet E. Pope, MD, MPH, FRCPC, of the Division of Rheumatology, University of Western Ontario, spoke about the results of open-label, long-term extension studies of tofacitinib for the treatment of patients with rheumatoid arthritis.

Pope said researchers found consistent safety and sustained efficacy over 84 month for patients with rheumatoid arthritis who received 5-mg or 10-mg tofacitinib twice daily.